Zhejiang Jingxin Pharmaceutical Co., Ltd. (SHE:002020)

SHE:002020 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Operating Revenue	4,203	3,920	3,717	3,401	3,214	3,604
Other Revenue	78.89	78.89	62.81	65.06	44.25	42.23
Revenue	4,282	3,999	3,780	3,467	3,258	3,647
Revenue Growth (YoY)	9.65%	5.79%	9.04%	6.40%	-10.66%	23.88%
Cost of Revenue	2,123	1,988	1,774	1,547	1,277	1,282
Gross Profit	2,159	2,011	2,006	1,920	1,981	2,364
Selling, General & Admin	1,029	994.61	984.94	970.72	1,178	1,588
Research & Development	410.78	400.79	367.04	334.14	257.91	252.58
Other Operating Expenses	34.28	30.09	36.19	26.57	28.02	35.39
Operating Expenses	1,499	1,432	1,392	1,342	1,462	1,878
Operating Income	660.66	579.08	613.8	577.8	519.31	486
Interest Expense	-8.33	-7.31	-6.01	-4.97	-6	-10.61
Interest & Investment Income	81.59	66.71	85.05	96.29	79.73	88.75
Currency Exchange Gain (Loss)	3.43	3.43	14.43	-3.84	-9.77	1.75
Other Non Operating Income (Expenses)	-7.78	-0.97	-3.21	-7.19	-9.77	-1.73
EBT Excluding Unusual Items	729.57	640.94	704.06	658.09	573.49	564.16
Impairment of Goodwill	-	-	-	-	-	-1.6
Gain (Loss) on Sale of Investments	24	24.44	10.15	7.23	131.49	1.59
Gain (Loss) on Sale of Assets	2.58	6.86	0.61	-0.48	-0.04	-2.07
Asset Writedown	-1.39	-0.01	-0.07	-8.42	-0.51	-0.74
Other Unusual Items	93.66	35.81	35.56	43.12	54.54	42.08
Pretax Income	848.41	708.04	750.32	699.54	758.98	603.41
Income Tax Expense	120.39	84.62	82.49	81.57	105.65	81.47
Earnings From Continuing Operations	728.02	623.42	667.82	617.96	653.33	521.95
Minority Interest in Earnings	-6.74	-4.52	-5.57	-5.42	-0.26	-1.55
Net Income	721.29	618.9	662.25	612.54	653.07	520.4
Net Income to Common	721.29	618.9	662.25	612.54	653.07	520.4
Net Income Growth	8.77%	-6.55%	8.12%	-6.21%	25.49%	40.92%
Shares Outstanding (Basic)	859	860	860	817	796	855
Shares Outstanding (Diluted)	859	860	860	817	796	855
Shares Change (YoY)	-0.29%	-0.06%	5.31%	2.55%	-6.90%	-1.28%
EPS (Basic)	0.84	0.72	0.77	0.75	0.82	0.61
EPS (Diluted)	0.84	0.72	0.77	0.75	0.82	0.61
EPS Growth	9.09%	-6.49%	2.67%	-8.54%	34.80%	42.86%
Free Cash Flow	646.77	273.32	340.2	-33.37	179.21	197.97
Free Cash Flow Per Share	0.75	0.32	0.40	-0.04	0.23	0.23
Dividend Per Share	0.300	0.300	0.300	0.300	0.292	0.292
Dividend Growth	0%	0%	0%	2.85%	0%	16.68%
Gross Margin	50.43%	50.30%	53.06%	55.39%	60.80%	64.84%
Operating Margin	15.43%	14.48%	16.24%	16.67%	15.94%	13.33%
Profit Margin	16.84%	15.48%	17.52%	17.67%	20.04%	14.27%
Free Cash Flow Margin	15.10%	6.84%	9.00%	-0.96%	5.50%	5.43%
EBITDA	895.39	778.68	766.56	713.89	642.51	592.21
EBITDA Margin	20.91%	19.47%	20.28%	20.59%	19.72%	16.24%
D&A For EBITDA	234.73	199.6	152.76	136.09	123.2	106.21
EBIT	660.66	579.08	613.8	577.8	519.31	486
EBIT Margin	15.43%	14.48%	16.24%	16.67%	15.94%	13.33%
Effective Tax Rate	14.19%	11.95%	10.99%	11.66%	13.92%	13.50%
Revenue as Reported	4,282	3,999	3,780	3,467	3,258	3,647
Advertising Expenses	-	-	-	5.13	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.